Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop combination shots

Novavax has entered into a significant agreement with Sanofi, involving a multibillion-dollar deal to co-commercialize Novavax's Covid vaccine and develop new combination vaccines. This partnership, starting next year, will leverage Novavax's Matrix-M adjuvant technology for future vaccine products. The deal also includes financial terms favorable to Novavax, such as upfront and milestone payments, royalties, and a minor equity stake for Sanofi in Novavax. This collaboration marks a crucial turnaround for Novavax, addressing its previous financial concerns and expanding its global vaccine reach and development capabilities.